Hamptons Homebuildi...
Health Care: Drugs
Elan Corp PLC (ELN: NYSE)
$12.47 0.11 | 0.89%
05/24/13 - 04:04 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -137.40M | 560.50M | -324.70M | -176.20M |
| Operating Gains/Losses | 335.80M | -575.30M | 12.00M | -103.10M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -25.80M | 23.90M | 800.00K | 3.70M |
| (Increase) Decrease in Inventories | -1.10M | 15.20M | 14.20M | -24.30M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 42.10M | -213.50M | 33.00M | 29.90M |
| (Decrease) Increase In Other Current Liabilities | -2.10M | -6.90M | -700.00K | 4.30M |
| (Increase) Decrease In Other Working Capital | 6.50M | -70.90M | 0.00 | 0.00 |
| Other Non-Cash Items | 110.10M | 108.40M | 254.50M | 115.90M |
| Net Cash From Continuing Operations | 55.30M | -120.20M | 68.20M | -86.30M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 55.30M | -120.20M | 68.20M | -86.30M |
| Sale of Property, Plant & Equipment | 0.00 | 1.30M | 100.00K | 7.30M |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 300.00K | 8.50M | 28.90M |
| Purchases of Property, Plant & Equipment | -12.10M | -29.80M | -44.50M | -95.90M |
| Acquisitions | 380.90M | 500.00M | 4.30M | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 11.30M | 186.80M | -191.40M | 3.50M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 303.20M | 660.50M | -216.00M | -56.80M |
| Issuance of Debt | 587.90M | 0.00 | 187.10M | 603.00M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 20.80M | 6.30M | 0.00 | 872.00M |
| Repayment of Long-Term Debt | -682.50M | -697.30M | -455.00M | -867.80M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | -125.00M | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 1.80M | -3.10M |
| Net Cash From Financing Activities | -198.80M | -691.00M | -266.10M | 604.10M |
| Effect of Exchange Rate Changes | -100.00K | -100.00K | -100.00K | 200.00K |
| Net Change in Cash & Cash Equivalents | 159.60M | -150.80M | -414.00M | 461.20M |
Portfolios with ELN
- Portfolio NameUser Type
- ContributorMost-Active Stocks for the ...
- ContributorMost-Active Stocks for the ...
- ProTPG-Axon Capital
- Contributor22 Biopharma Stocks With Br...
- UserGFNN Stockdiagnostics 13
- ContributorBreakout Stocks Of The Week...
- UserGFNN Stockdiagnostics
- ContributorRelative Strength Trades fo...
- ContributorStocks At New 52-Week Highs...
- ProRobert Bruce
Latest ELN Headlines from TheStreet
- Dollar Strength Hits Oil, Gold
05.13.13 | 08:05 am - Stock Futures Lower Ahead of Retail Sales 05.13.13 | 06:05 am
- Why This Fund Manager Is Short Ziopharm 03.22.13 | 07:03 am
- SAC to Pay Record Insider Trading Penalty 03.16.13 | 11:03 am
- Dow Sets Another Record as Stocks Rise 03.11.13 | 04:03 pm
- You Have to Love a Lucrative 'Drug Deal' 02.28.13 | 06:02 am
- Royalty Pharma: Don't Let Elan Piss Away $3 Billion On Stupid Acquisitions 02.25.13 | 09:02 am
- 2 Hot Stocks to Trade (or Not) 02.07.13 | 02:02 pm
- Before the Bell: Feb. 6 02.06.13 | 08:02 am
- The Digital Skeptic: Insider Trading? Why Even Bother? 12.04.12 | 08:12 am
Press Releases for ELN
- Royalty Pharma Discloses Acceptance Levels Of Original Offer For Elan Pursuant To Irish And United States Regulatory Requirements - PR Newswire 05.24.13 | 07:05 am
- Royalty Pharma Reduces Acceptance Condition To 50% Plus One Share - PR Newswire 05.23.13 | 06:05 am
- Royalty Pharma Increases Offer For Elan To $12.50 Per Share In All Cash - PR Newswire 05.20.13 | 11:05 am
- Royalty Pharma Submits Formal Cash Offer For Elan Corporation, Plc ("Elan") - PR Newswire 05.02.13 | 07:05 am
- Royalty Pharma Announces Firm Offer To Acquire Elan - PR Newswire 04.15.13 | 07:04 am
- New TYSABRI Data Reaffirm Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status - Business Wire 03.18.13 | 07:03 am
- Elan Discloses Filing Of Share Repurchase Tender Offer Documentation - Business Wire 03.12.13 | 01:03 pm
- Elan Provides Update On Tysabri Transaction And $1bn Share Repurchase - Business Wire 03.08.13 | 04:03 pm
- Elan’s Response To Royalty Pharma Statement Of Today - Business Wire 03.06.13 | 09:03 am
- Elan Announces Further Unlocking Of Value To Benefit Shareholders - Business Wire 03.04.13 | 01:03 am
Partner Headlines for ELN
- Acorda: A Biotech Company To Consider - Seeking Alpha 04.13.13 | 09:04 am
- Benzinga's Top Pre-Market Gainers - Benzinga 04.12.13 | 09:04 am
- After Hours Most Active for Feb 6, 2013 : T, BMY, FCX, KMI, NOK, HCBK, QQQ, ELN, GMCR, VMED, NWSA, WCRX - NASDAQ 02.06.13 | 09:02 pm
- Stocks Lower In Choppy Trade; Aruba, Trimble Slide - Investor's Business Daily 02.06.13 | 03:02 pm
- Pre-Market Most Active for Feb 6, 2013 : ELN, QQQ, BAC, BBRY, ZNGA, NOK, GSK, VMED, KB, SNY, ARMH, CLDX - NASDAQ 02.06.13 | 01:02 pm
- Biogen Stock Hits New High On Tysabri Buyout - Investor's Business Daily 02.06.13 | 10:02 am
- Alkermes Trades Tightly, Holds In Buying Range - Investor's Business Daily 01.17.13 | 02:01 pm
- Alkermes' Acquisition Proves To Be Game-Changer - Investor's Business Daily 11.30.12 | 05:11 pm
- Dissecting George Soros' Recent Moves, Part 4: Stake Reductions And Liquidations - Seeking Alpha 11.24.12 | 08:11 am
- Feds Circling SAC Capital; Mathew Martoma Goes Down in $276 Million Insider Trading Sting - Benzinga 11.21.12 | 05:11 pm
